Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04554-3 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Mats Någård und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 208…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca.
Abstract (Originalsprache)
Purpose
Adavosertib may alter exposure to substrates of the cytochrome P450 (CYP) family of enzymes. This study assessed its effect on the pharmacokinetics of a cocktail of probe substrates for CYP3A (midazolam), CYP2C19 (omeprazole), and CYP1A2 (caffeine).
Methods
Period 1: patients with locally advanced or metastatic solid tumors received ‘cocktail’: caffeine 200 mg, omeprazole 20 mg, and midazolam 2 mg (single dose); period 2: after 7- to 14-day washout, patients received adavosertib 225 mg twice daily on days 1–3 (five doses), with cocktail on day 3. After cocktail alone or in combination with adavosertib administration, 24-h pharmacokinetic sampling occurred for probe substrates and their respective metabolites paraxanthine, 5-hydroxyomeprazole (5-HO), and 1′-hydroxymidazolam (1′-HM). Safety was assessed throughout.
Results
Of 33 patients (median age 60.0 years, range 41–83) receiving cocktail, 30 received adavosertib. Adavosertib co-administration increased caffeine, omeprazole, and midazolam exposure by 49%, 80%, and 55% (AUC 0–12 ), respectively; AUC 0–t increased by 61%, 98%, and 55%. Maximum plasma drug concentration (C max ) increased by 4%, 46%, and 39%. Adavosertib co-administration increased 5-HO and 1′-HM exposure by 43% and 54% (AUC 0–12 ) and 49% and 58% (AUC0–t), respectively; paraxanthine exposure was unchanged. Adavosertib co-administration decreased C max for paraxanthine and 5–HO by 19% and 7%; C max increased by 33% for 1′-HM. After receiving adavosertib, 19 (63%) patients had treatment-related adverse events (six [20%] grade ≥ 3).
Conclusion
Adavosertib (225 mg bid) is a weak inhibitor of CYP1A2, CYP2C19, and CYP3A. ClinicalTrials.gov NCT03333824
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Mats.Nagard@astrazeneca.com.
- Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK.
- Mary Crowley Cancer Research Center, Dallas, TX, USA.
- University of Cincinnati Cancer Center, Cincinnati, OH, USA.
- Rhode Island Hospital, Lifespan Cancer Institute, Providence, RI, USA.
- Beaumont Cancer Center, Royal Oak, MI, USA.
ORCID-Profile: Mats Någård
Förderung
- NCI NIH HHS
- AstraZeneca
Zitieren
APA
Någård, M., Ah-See, M. L., Strauss, J., Wise-Draper, T., Safran, H. P., Nadeau, L., Edenfield, W. J., Lewis, L. D., Ottesen, L. H., Li, Y., & Mugundu, G. M. (2023). Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04554-3
Vancouver
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, et al. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04554-3
BibTeX
@article{Ngrd2023,
author = {Någård, Mats and Ah-See, Mei-Lin and Strauss, James and Wise-Draper, Trisha and Safran, Howard P and Nadeau, Laura and Edenfield, William J and Lewis, Lionel D and Ottesen, Lone H and Li, Yan and Mugundu, Ganesh M},
title = {Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04554-3}
}
EUVIMED